Literature DB >> 6096852

Highly selective photoaffinity labeling of mu and delta opioid receptors.

C Garbay-Jaureguiberry, A Robichon, V Daugé, P Rossignol, B P Roques.   

Abstract

We report the synthesis and photolabeling properties of two highly selective ligands for mu and delta opioid-binding sites: Tyr-D-Ala-Gly-MePhe (pN3)-Gly-ol (AZ-DAMGE) and Tyr-D-Thr-Gly-Phe (pN3)-Leu-Thr (AZ-DTLET). An irreversible inhibition of the electrically induced contractions of mouse vas deferens is caused by irradiation (at 254 nm) of the muscle strip in the presence of AZ-DTLET (1 nM). This phenomenon is antagonized only at large concentrations (10 microM) of naloxone, in accordance with the well-known lower selectivity of naloxone for delta sites. Competition experiments with [3H]DAMGE and [3H]DTLET on crude rat brain membranes showed that the azido photoprobes display a similar (AZ-DAMGE) and even a better (AZ-DTLET) selectivity than their respective parent compounds DAMGE and DTLET. Up to 25 nM, AZ-DTLET irreversibly and selectively photolabels the delta sites of crude rat brain homogenates. Due to its lower affinity AZ-DAMGE provides similar selective photolabeling of the mu sites but at higher concentrations (approximately equal to 0.3 microM). When [3H]DAMGE and [3H]DTLET were used as ligands for mu and delta binding subtypes, respectively, no important change in binding capacity and affinity of one receptor type was observed after photolabeling of the other.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6096852      PMCID: PMC392223          DOI: 10.1073/pnas.81.24.7718

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Irreversible ligands with high selectivity toward delta and mu opiate receptors.

Authors:  K C Rice; A E Jacobson; T R Burke; B S Bajwa; R A Streaty; W A Klee
Journal:  Science       Date:  1983-04-15       Impact factor: 47.728

2.  Solubilization and characterization of mu, delta, and kappa opioid binding sites from guinea pig brain: physical separation of kappa receptors.

Authors:  Y Itzhak; J M Hiller; E J Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

3.  Isolation of opiate binding components by affinity chromatography and reconstitution of binding activities.

Authors:  T M Cho; B L Ge; C Yamato; A P Smith; H H Loh
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

4.  Photolabile opioid derivatives of D-Ala2-Leu5-enkephalin and their interactions with the opiate receptor.

Authors:  C Zioudrou; D Varoucha; S Loukas; N Nicolaou; R A Streaty; W A Klee
Journal:  J Biol Chem       Date:  1983-09-25       Impact factor: 5.157

5.  The mu rather than the delta subtype of opioid receptors appears to be involved in enkephalin-induced analgesia.

Authors:  P Chaillet; A Coulaud; J M Zajac; M C Fournie-Zaluski; J Costentin; B P Roques
Journal:  Eur J Pharmacol       Date:  1984-05-18       Impact factor: 4.432

6.  Improved assays for the assessment of kappa- and delta-properties of opioid ligands.

Authors:  S J Ward; P S Portoghese; A E Takemori
Journal:  Eur J Pharmacol       Date:  1982-11-19       Impact factor: 4.432

7.  Photolabile ligands for opiate receptors.

Authors:  C Zioudrou; D Varoucha; S Loukas; R A Streaty; W A Klee
Journal:  Life Sci       Date:  1982 Oct 18-25       Impact factor: 5.037

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.

Authors:  T Chow; R S Zukin
Journal:  Mol Pharmacol       Date:  1983-09       Impact factor: 4.436

10.  Deltakephalin, Tyr-D-Thr-Gly-Phe-Leu-Thr: a new highly potent and fully specific agonist for opiate delta-receptors.

Authors:  J M Zajac; G Gacel; F Petit; P Dodey; P Rossignol; B P Roques
Journal:  Biochem Biophys Res Commun       Date:  1983-03-16       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.